This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Kamboj M , Brite J , Aslam A , Kennington J , Babady NE , Calfee D , Furuya Y , Chen D , Augenbraun M , Ostrowsky B , Patel G , Mircescu M , Kak V , Tuma R , Karre TA , Fry DA , Duhaney YP , Moyer A , Mitchell D , Cantu S , Hsieh C , Warren N , Martin S , Willson J , Dickman J , Knight J , Delahanty K , Flood A , Harrington J , Korenstein D , Eagan J , Sepkowitz K
Artificial differences in clostridium difficile infection rates associated with disparity in testing
Emerg Infect Dis. 2018 Mar;24(3) :584-587
PMID: 29460760 PMCID: PMC5823336 URL: https://www.ncbi.nlm.nih.gov/pubmed/29460760
AbstractIn 2015, Clostridium difficile testing rates among 30 US community, multispecialty, and cancer hospitals were 14.0, 16.3, and 33.9/1,000 patient-days, respectively. Pooled hospital onset rates were 0.56, 0.84, and 1.57/1,000 patient-days, respectively. Higher testing rates may artificially inflate reported rates of C. difficile infection. C. difficile surveillance should consider testing frequency.
NotesExport Date: 1 March 2018